Clinical Trial Update: Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections [Phase 3]

View source ↗

Summary

Phase 3 trial comparing single-dose versus two-dose dalbavancin regimens for acute bacterial skin and skin structure infections completed with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Abscess
• Bacterial Skin and Skin Structure Infections
• Cellulitis
• Surgical Site Infection
• Wound Infection

Drugs mentioned

• Dalbavancin (dalbavancin)

Snippet

Sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc | Conditions: Abscess, Wound Infection | Phase 3 | Status: COMPLETED | Results posted: 2018-08-14